14th International

MOLECULAR MEDICINE
Tri-Conference

Conference Dates: February 27 - March 2, 2007
Exhibit Dates: February 28 - March 1, 2007
Moscone North Convention Center • San Francisco, CA

1. Pathway Analysis
2. Global Strategies Executive Summit
3. Mastering Medicinal Chemistry
4. Preclinical Development
5. Molecular Diagnostics
6. Commercializing Stem Cells
7. Clinical Trials in India & Asia
8. Trends in Drug Safety
9. Cancer Molecular Markers

Premier Sponsors:

Corporate Sponsors:

Co-Sponsor:

THE WALL STREET JOURNAL

Lead Sponsoring Publications:

Book Early!
The first 50 to register by October 27 will receive a copy of G. Steven Burill’s Biotech 2006 - Life Sciences Book. (See details on page 2)

Plus! Save up to $350!

Access to all 9 Tracks One Price!

www.Tri-Conference.com
**Pre-Conference Events • February 27, 2007**

### The Biotech Pharma Partnership

**Part I: Trends in Alliances, Collaborations, Acquisitions, and Other Sources of Capital: Executive Lectures and Moderated Panel • 8-11:30am**

Distinguished Faculty and Advisors:
- Wendy Benson, Ph.D., Senior Director, Business Development, Roche Molecular Diagnostics
- Arthur H. Berteon, Ph.D., Executive Director, Discovery Collaborations & Technology Licensing, Schering-Plough Research Institute
- T. (Tess) Forrest Dagi, MD, MPH, MBA, FACS, FCCM, HLM Venture Partners & Harvard-MIT Division of Health Sciences and Technology (HST) Faculty
- Jack DeForest, Ph.D., Vice President of Technology Licensing, Product Acquisition and Licensing, GE Healthcare
- Kendra B. Eager, Ph.D., Assistant Vice President, Alliance Management, Wyeth Global Business Development
- Cynthia Grant, Ph.D., Associate Global Alliance Director, Global Sciences and Information, AstaRena Pharmaceuticals
- Stefanie Hansen, J.D., Director, Strategic Alliances, Pfzer Global Research and Development
- Robert C. Hockney, Ph.D., Director, Global Discovery Alliances, GSI, AstaRena R&D
- Rosemarie Hurezky, Ph.D., Director, Technology Development and Industrial Relations, Center for Biotechnology and Innovation, National Institute of Dental and Craniofacial Research, National Institutes of Health
- Jeremy Loxm, D. Phil, MB, BChir, Global Head, Business Development and Strategic Alliances, Novartis
- Kelly P. Longo, Ph.D., Director, Strategic Alliances, Pfzer Inc.
- John Buesnick, Patent Attorney, Senior Partner, Banner & Witcoff, Ltd.
- Joan Lavota, Ph.D., Senior Director Alliance Management, Merck & Co.
- Michael O. Ransom, Ph.D., Alliance Manager, Eli Lilly & Co., Lilly Corporate Center, Lilly Research Labs
- Sandra Rivett, Ph.D., Associate Global Alliance Director, Global Sciences and Information, AstaRena Pharmaceuticals
- Steven Tregay, Ph.D., Head of Strategic Alliances Technology, Novartis

Keynote Topics & Panel Discussion will include presentations on:
- Alliance Management
- Licensing and Protecting Assets
- Mergers and Acquisitions
- The Strategic Role of Partnerships and other Collaborations that Fund the Pipeline

**Part II: Early Stage Company Presentations, Executive Coaching & Didactic Panel Critiques • 1-4pm**

Three concurrent sessions:
- Diagnostics
- Biomarkers
- Cancer Therapeutics

Each session will be moderated and critiqued by the part I program experts in Alliances, Licensing, Funding, and Intellectual Property. Selected early stage companies have been reviewed and selected by our scientific and business advisors. (Limited openings still available). Please contact samster@healthtech.com

**Roundtable Networking Reception Discussion Groups**

“Meet and Greet” executive speakers, panelists and early stage company representatives at moderated roundtable networking discussions.

**One-to-One Meetings Available all Week Using CHI’s Intro-Net**

### Short Courses (SC)

#### MORNING

| (SC1) | The Biotech Pharma Partnership - Part I |
| (SC2) | Global Strategies Morning Course |
| (SC3) | Novel Therapies for CNS Disorders - Crossing the Blood-Brain Barrier |
| (SC4) | Microreactors: Integrating Flow Chemistry into Drug Discovery |
| (SC5) | Circulating Tumor Cells (CTCs) as Biomarkers and their use in Oncology |
| (SC6) | Preclinical Morning Course |

#### AFTERNOON

| (SC7) | Diagnostics |
| (SC8) | Biomarkers |
| (SC9) | Cancer Therapeutics |
| (SC10) | An Interactive Workshop Including a Business War Game: Does Your Strategy Hurt When I Do This? |
| (SC11) | ADMET Case Studies from a Medicinal Chemistry Perspective |
| (SC12) | Multi-Plexing and Multi-Probing using Late-PCR and Sloppy Beacons: Applications in Quantitative End-Point Detection |
| (SC13) | Microdosing |
| (SC14) | Stem Cell Afternoon Course |
| (DC15) | New Ways to Partner in the Personalized Medicine Space |

#### DINNER

**CONFERENCE-AT-A-GLANCE**

<table>
<thead>
<tr>
<th>Tuesday, February 27</th>
<th>Wednesday, February 28</th>
<th>Thursday, March 1</th>
<th>Friday, March 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pathway Analysis</td>
<td>1 Pathway Analysis</td>
<td>1 Pathway Analysis</td>
</tr>
<tr>
<td>2</td>
<td>Global Strategies to Reinv</td>
<td>2 Global Strategies to Reinv</td>
<td>2 Global Strategies to Reinv</td>
</tr>
<tr>
<td>3</td>
<td>Mastering Medicinal Chemistry</td>
<td>3 Mastering Medicinal Chemistry</td>
<td>3 Mastering Medicinal Chemistry</td>
</tr>
<tr>
<td>4</td>
<td>Predictive Preclinical Development</td>
<td>4 Predictive Preclinical Development</td>
<td>4 Predictive Preclinical Development</td>
</tr>
<tr>
<td>5</td>
<td>Molecular Diagnostics</td>
<td>5 Molecular Diagnostics</td>
<td>5 Molecular Diagnostics</td>
</tr>
<tr>
<td>6</td>
<td>Commercial Implications of Stem Cell Research</td>
<td>6 Commercial Implications of Stem Cell Research</td>
<td>6 Commercial Implications of Stem Cell Research</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Trials in India &amp; Asia</td>
<td>7 Clinical Trials in India &amp; Asia</td>
<td>7 Clinical Trials in India &amp; Asia</td>
</tr>
<tr>
<td>8</td>
<td>Trends in Drug Safety</td>
<td>8 Trends in Drug Safety</td>
<td>8 Trends in Drug Safety</td>
</tr>
<tr>
<td>9</td>
<td>Cancer Molecular Markers</td>
<td>9 Cancer Molecular Markers</td>
<td>9 Cancer Molecular Markers</td>
</tr>
</tbody>
</table>

**Book Early!***

The first 50 people to register by October 27 will receive a complimentary copy of G. Steven Burrill’s Biotech 2006—Life Sciences: A Changing Prescription book and save up to $350 off your event registration!

*Promotional Terms:
- 3-day registration + 3 Short Courses must be paid in full by October 27, 2006
- A $395 cancellation fee will be incurred on any cancellation that qualifies for the Book Early Promotion. ($100 processing fee and $195 for the cost of the Biotech 2006 - Life Science Book.)
- Book Early - Life Science Book will be shipped out the week after the October 27th deadline

[www.Tri-Conference.com](http://www.Tri-Conference.com)
**PLENARY KEYNOTES**

**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**
Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.

**Partnering and Alliance Trends**
Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

---

**PATHWAY DATABASES FOR CANCER RESEARCH**

Dr. Nathan Siemers, Director of Bioinformatics, Bristol-Myers Squibb Company

**The New Kid on the Block: microRNA Profiling in Cancer from a Bioinformatics Perspective**
Yuriy Gusev, Ph.D., Assistant Professor, Department of Surgery, Adjunct Assistant Professor, Institute for Breast Health, Co-Director, Bioinformatics Core facilities, OU Cancer Center, University of Oklahoma

**OPEN SOURCE PATHWAY INFORMATION: OPPORTUNITIES AND CHALLENGES**

GenMAPP
Bruce R. Conklin, M.D., Associate Investigator Gladstone Institute of Cardiovascular Disease, Associate Professor of Medicine, University of California, San Francisco

**Open Source Pathways Databases: The Reactome Example**
Peter G. d’Eustachio, Ph.D., Editor-in-Chief, Reactome, and Associate Professor of Biochemistry and Medicine, Departments of Biochemistry and Medicine, New York University School of Medicine

**Pathway Commons - Convenient Access to Pathway Information**
Gary Bader, Ph.D., Assistant Professor, Banting and Best Department of Medical Research, University of Toronto

**Integrating Genetic, Functional Genomic, and Bioinformatic Data in a Systems Biology Approach to Complex Diseases (Cytoscape)**
Allan Kachirski, Principal Project Scientist, Molecular Technologies Lab, Agilent Laboratories

**RNAI SCREENS FOR TARGET DISCOVERY**

**RNAi Screens for Target Discovery in Metabolic Disease**
Michael P. Czech, Ph.D., Professor and Chair, Program in Molecular Medicine, University of Massachusetts Medical School

**RNAi-Based High-Content Screening for Target Identification**
John F. Reidhaar-Olson, Ph.D., Research Leader, Department of Research Informatics, University of Massachusetts Medical School

**Screening for Drugable Inflammation Targets**
Zakina Strezoska, Ph.D., Senior Scientist, ALTANA Pharma AG

**Robust, Image-Based, RNAi Screens for Oncology Drug Target Identification**
Steven A. Haney, Ph.D., Group Leader, Oncology Genomics, Department of Biological Technologies, Wyeth Research

**High-Throughput RNAi Screening by Time-Lapse Imaging of Live Human Cells**
Jan Ellenberg, Ph.D., Gene Expression & Cell Biology & Biophysics, MitoCheck Project Group, European Molecular Biology Laboratory (invited)

---

**EXPANDING WORLD OF microRNAs: NEW AVENUES FOR DIAGNOSTICS AND THERAPY**

**miRNAs: Biomarkers for Cancer?**
Aimee Jackson, Ph.D., Research Fellow, Rosetta Inpharmatics, a wholly-owned subsidiary of Merck & Co., Inc.

**microRNA as Cancer Biomarkers**
David Brown, Ph.D., Head of R&D, AstraZeneca, Inc.

**Genomics of Chronic Lymphocytic Leukemia microRNAs as New Players with Clinical Significance**
George Calin, M.D., Ph.D., Research Assistant Professor, Molecular Virology, Immunology & Medical Genetics Department, Comprehensive Cancer Center, Ohio State University

**microRNAs in Proliferation and Differentiation**
Anindya Dutta, M.D., Ph.D., Byrd Professor of Biochemistry and Molecular Genetics, University of Virginia

---

**USE OF ANIMAL MODELS TO VALIDATE GENE EXPRESSION SIGNATURES**

**Cholinergic Angiogenesis -- A Novel Endogenous Angiogenic Pathway and its Therapeutic Application to Diseases**
Jenny Wu, Ph.D., Senior Research Scientist, Cardiovascular Medicine, Stanford University

**Understanding Anti-Proliferation Mechanism in Animal Models by Genomic Approaches**
Chris Huang, Ph.D., Principal Research Scientist, Discovery Research, Centocor Research & Development, Inc.

**Organ-Specific Metastasis and Molecular Signatures**
Andrew J. Minn, M.D., Ph.D., Assistant Professor, Department of Radiation Oncology, University of Chicago (tentative)

**Reversible Type-2 Diabetes Mouse Model Through Doxycycline Regulated ShRNA Expression**
Jost Seibler, Ph.D., RNAi Group Leader, Artemis Pharmaceuticals

**Understanding Transcriptional Networks with Cap Analysis Gene Expression (CAGE)**
Piero Carninci, Ph.D., Genome Science Laboratory, RIKEN

---

**CANCER MOLECULAR MARKERS**

(Shared session with Molecular Diagnostics)

**Developing Pharmacodiagnostics for Cancer**
Jan Trost Jorgensen, M.S., Pharm, Ph.D., Principal Scientist, Clinical Research, Dako

**Biomarkers and Development of Targeted Therapies**
Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline

**Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective**
Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor

**Driving Down Development Costs by Using Biomarkers**
Karel Sikora, M.A., MBBCh, Ph.D., FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC

**Detection of Cancer through Circulating DNA**
Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)
Fifth Annual R&D Executive Summit

INTEGRATE Licensing, Alliance management, International Collaborations and Lean Thinking Into Your Organization

February 28-March 2, 2007

PRE-CONFERENCE SHORT COURSES (SC)

Panel Discussion

**Strategies for Successful Outsourcing of Preclinical Development in Asia**
Chairperson: Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.

Chairperson’s Remarks
Bala Balasubramanian, Ph.D., Director, Discovery Chemistry, Bristol-Myers Squibb Co.

**Strategies to Minimize IP Risk and Maximize Protection in the Rapidly Developing Legal Landscape**

**Capitalizing on Asia’s Unique Characteristics to Improve R&D’s Productivity**
Eric Morfin, Director, Project Management Office, Novartis Vaccines and Diagnostics

**Building a High-Performing, Multinational R&D Organization in China**

Case Study

Opportunities and Pitfalls of Establishing an R&D Service Organization in India
Antal K. Haji, Ph.D., Managing Director, ALTANA Pharma Pvt. Ltd.

Case Study

The Impacts of and Strategies for Outsourcing of Medicinal Chemistry
M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.

Frederik Denousse, Ph.D., Head, External Chemistry & Outsourcing Services, J&J PRD

STRAteGies FOR LOWERING ATTRITION, IMPACTING SUCCESS AT PROOF-OF-CONCEPT & IMPROVING PROCESSseS

Chairpersons’ Remarks
Mark I. Cockett, Ph.D., Vice President, Applied Genomics, Bristol-Myers Squibb Co.

**R&D Productivity Levers - Are all Productivity Improvements Equal?**

Aaron Schacht, Executive Director, R&D Strategy, Portfolio & Project Management, Eli Lilly

**Is Drug Discovery Ready for Lean Thinking?**

Edward W. Pettillo, Ph.D., retired Distinguished Research Fellow, Bristol-Myers Squibb Co.; President, Discovery Performance Strategies LLC

**Peptide Therapies and Research Program Planning: Marrying Research Innovation with Project, Portfolio and Resource Management to Deliver Significant New Peptide-Based Therapeutics**

James Paterniti, Ph.D., Senior Director, Research Program Planning, Amylin Pharmaceuticals, Peptide Therapies and Research Program Planning: Marrying Research

**Learning from Non-Pharma Industries: Understanding Others’ Mastery of Clinical Development**
Matthew Bell, Ph.D., MA, Senior Director, Learn and Confirm Implementation Office, Wyeth

**How Wyeth is Transforming R&D: The Learn and Confirm Model of Clinical Development**

**Topic to Be Announced**
Christine Cioffe, Vice President, R&D Portfolio Management, Merck & Co.

SUCCESSING IN A FUTURE OF HIGH ATTRITION BY EFFECTIVELY MANAGING R&D PROJECTS AND PROCESSES

Chairperson’s Remarks
Edward W. Pettillo, Ph.D., retired Distinguished Research Fellow, Bristol-Myers Squibb Co.; President, Discovery Performance Strategies LLC

**Life Science Industries - Managing a Turbulent Future**
Professor Joyce Tait, CBE, FRSE, Ph.D., Director, ESRC Innogen Centre (Centre for Social and Economic Research on Innovation in Genomics), University of Edinburgh

**R&D Performance Measurements: More than Choosing a Set of Metrics**
Shama Kajiji, Ph.D., MBA, Director, WorldWide Project Management, Pfizer Inc.

Panel Discussion

Effectively Managing R&D Projects and Processes: Successes and Failures
LEARN Strategies to Tackle Difficult Targets in Multiple Therapeutic Areas

**PRE-CONFERENCE SHORT COURSES (SC)**

**February 27, 2007**

(SC3) Novel Therapies for CNS Disorders - Crossing the Blood-Brain Barrier
- Novel Targets Identification and Validation
- Novel Delivery Strategies
- Dealing with the Liability of CNS Drug Side-effects
- Crossing the Blood-Brain Barrier - BBB Penetration
- Pharmacokinetics and Drug Metabolism

(SC4) Microreactors: Integrating Flow Chemistry into Drug Discovery
- The Challenges of Switching from Batch to Flow Chemistry
- Scaling Up and Improving Safety
- Reproducibility
- Performing Reactions with Different Solvents
- Handling Precipitates and Solids – Is there a “Solution” in Sight?
- Are Microreactors Ready for General Use in Drug Discovery Laboratories?

(SC11) ADMET Case Studies from a Medicinal Chemistry Perspective
- Understanding How to Evaluate ADME Data
- Diagnostic PK Assays
- QSAR for Medicinal Chemistry
- Case Studies from Real Projects

**PLENARY KEYNOTE**

**Partnering and Alliance Trends**

Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

**EXECUTIVE OVERVIEW – FUTURE DIRECTIONS FOR MEDICINAL CHEMISTRY**

**Featured Speaker**

**Lead Generation for Difficult Targets**

Hanno Wild, Head of Discovery Europe, Bayer HealthCare AG

Over the last ten years Bayer HealthCare has built up its compound library to almost 2 million single compounds. In parallel, ultra high-throughput screening in the 1536 format was established as the standard technique for lead finding. The success of this approach could be demonstrated by the discovery of novel lead structures for targets which were difficult to approach so far: Non-basic inhibitors of Factor Xa, competitive inhibitors of human neutrophil elastase, non-nucleosidic adenosine agonists.

**THE IMPACT OF OUTSOURCING AND OFF-SHORING ON MEDICINAL CHEMISTRY**

- Maintaining corporate growth while increasing project capacity
- The impact of library and hit-to-lead outsourcing on medicinal chemistry
- Can current outsourcing companies provide adequate medicinal chemistry?
- Retraining medicinal chemists in more creative and higher skilled aspects of chemistry

Frederik Deroose, Ph.D., Head of External Chemistry & Outsourcing Services, Johnson & Johnson Pharmaceutical Research & Development

M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.

**DOMAIN DRIVEN MEDICINAL CHEMISTRY – DIFFERENT APPROACHES FOR CNS, CANCER, METABOLIC AND CHRONIC DISEASES**

**Metabolic Disorders**

Selective Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: The Discovery of JanuviaTM (Sitagliptin)

Scott D. Edmondson, Ph.D., Senior Research Fellow, Merck Research Laboratories

Metabolic Disease Target Validations using Small Molecule Agents: Compare and Contrast with Genetic Depletion Models

Gang Liu, Ph. D., Senior Group Leader, Associate Research Fellow, GPRD-Metabolic Disease Research, Abbott Laboratories

PTP1B Inhibitors: New Leads for a Challenging Drug Target via Structure-based Drug Design Methods

Andrew Combs, Ph.D., Senior Director, Chemistry, Incyte Corporation

Rational Design of Potent, Selective, Efficacious and Safe DPP4 Inhibitors as a Treatment of Type 2 Diabetes

Zhong-hua Pei, Ph.D., Research Investigator, Metabolic Disease Research Global Pharmaceutical Research & Development, Abbott Laboratories

Is Malonyl-coa Decarboxylase a Viable Therapeutic Target?

Jie-Fei Cheng, Ph.D., Director, Chemistry, Tanabe Research Laboratories USA

**Inflammation**

The Identification of Selective Lck Inhibitors for the Treatment of Solid Organ Transplant Rejection

Gavin Hirst, Ph.D., Associate Director, Medicinal Chemistry, Abbott Bioresearch Center

**Oncology**

Progesterone Receptor Antagonists - A Successfully Completed Lead Optimization Program

Wolfgang Schwede, Ph.D., Senior Scientist, Medicinal Chemistry, Schering AG

The Discovery of SKI-606: A Dual Inhibitor of Src and Abl Kinases in Clinical Development for the Treatment of Cancer

Diane H. Boschelli, Ph.D., Principal Research Scientist, Chemical and Screening Sciences, Wyeth Research

From the Insoluble Dye Indirubin Towards Highly Active, Soluble CDK2-Inhibitors

Rolf Jautelat, Ph.D., Principal Scientist, Medicinal Chemistry, Schering AG

**CNS**

New Pharmaceuticals from Neurotransmitters: Drugs for the Brain from the Brain

Robin Polt, Ph.D., Professor, Chemistry/Pharmacology, The University of Arizona

“...was one of the best conferences that I have been to in recent years. It combined intellectual stimulation with an exposure to the latest advances in medicinal chemistry. In addition it offered a unique opportunity to meet and talk with leaders in the field, as well as with colleagues involved in many diverse aspects of drug discovery and development.”

Anu Mahadevan, Ph. D., Vice President, Organix, Inc. (2006 Alumna)
PREDICTIVE PRECLINICAL DEVELOPMENT

February 28-March 2, 2007

OPTIMIZE candidate progression from DISCOVERY to EARLY CLINICAL evaluation

Panel Discussion

Strategies for Successful Outourcing of Preclinical Development in Asia
Chairperson: Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.

HOW MANY NEW BIOMARKERS DO WE NEED?
Cost-Benefit Analysis of New Biomarkers

Barriers on the Road to New Protein Biomarkers:
Confronting the Biomarker Validation Bottleneck
Leigh Anderson, Ph.D., Founder & Chief Executive Officer, Plasma Proteome Institute

Biomarkers, Biological Diversity, and Decision Making:
What to Measure, What it Means, and Why it has Value
Thomas Paterson, Co-founder, Senior Vice President, Entelos Inc.

START-PCR Measurement of Anti-Inflammatory Gene Transcript Abundance in Whole Blood Provides Accurate Biomarkers for RA Individuals
James C. Willey, M.D., Founder & Chief Science & Medical Consultant, Gene Express Inc. and Professor of Medicine and Pathology, George Isaac Professor for Cancer Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Toledo

Too Few Qualified Biomarkers for High Value Needs
Howard Schuman, Ph.D., Vice President, PPD Biomarker Discovery Sciences, LLC, and Consulting Professor of Neurobiology and of Molecular Pharmacology, Stanford University

Panel Discussion

Developing a Business Model for Risk Management of Innovative Technologies
- What is the added value?

CORRELATING IMAGING WITH CLINICAL EXPERIENCE

Keynotes

Richard Hargreaves, Ph.D., Vice President, Imaging, Merck & Co., Inc. (invited)
A. Gregory Sorensen, M.D., Director, Center for Biomarkers in Imaging, Associate Director, Martins Center for Biomedical Imaging, and Associate Professor of Radiology, Harvard Medical School and Massachusetts General Hospital

Image-Based Biomarker Quantifications
Edward Ashton, Ph.D., Chief Scientific Officer, VirtualScopics, Inc.

Affibody Molecules, a Novel Class of Affinity Ligands for Molecular Imaging of HER2-Positive Breast Cancer Preclinical and Clinical Applications
Joachim Feldwisch, Ph.D., Project Manager, Research, Affibody AB

Imaging Biomarkers for Cognitive Enhancing and Psychotropic Therapies
Cameron Carter, M.D., Imaging Research Center, U.C. Davis

“Again, the organizers of the Molecular Medicine Tri-Conference have compiled a group of outstanding speakers/scientists in the area of preclinical/clinical drug safety to address a variety of contemporary topics/issues of high interest in the fields of preclinical toxicology and drug development.”

George M., Vice President, Drug Safety & Disposition, Cephalon, Inc. (2006 Alumnus)
MOLECULAR DIAGNOSTICS:
Driving Quality of Care in Medicine
February 28-March 2, 2007

DISCOVER, CHOOS, VALIDATE, and INTRODUC biomarker products

Panel Discussion
Turning Discoveries into Clinical Products

Executive Strategy Panels
Diagnostic Wish List
Moderator: Harry Glorikian, Managing Partner, Strategic Advisory, TSG Partners
Panelists: Ronald M. Knaus, M.D., Senior Scientist and Director, Atherosclerosis Research, Children’s Hospital Oakland Research Institute; Guest Senior Scientist, Department of Genome Sciences, Lawrence Berkeley National Laboratory; and Adjunct Professor, Department of Nutritional Sciences, University of California, Berkeley
Personalized Medicine Coalition’s Landscape Analysis
Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition

Commercial Opportunities in Molecular Diagnostics
Moderator: Keith F. Batchelder, M.D., Chief Executive Officer and Founder, Genomic Healthcare Strategies
Panelists: Carol Reed, M.D., Senior Vice President and Chief Medical Officer, Clinical Data, Inc. (tentative)
Stéphane Barcel, Executive Vice President, bioMérieux sa
Jean-Luc Vanderheyden, Ph.D., Molecular Imaging Leader, GE Healthcare (invited)

UNDERSTANDING EPIGENETICS AND METHYLATION PATTERNS OF DISEASE
Epigenetics of Cancer Etiology
Andrew P. Feinberg, M.D., M.P.H., Professor, Molecular Medicine, Department of Medicine, Department of Oncology, Department of Molecular Biology & Genetics, Johns Hopkins University
QM-MSP-based Detection of Methylated Genes for Early Detection of Breast Cancer
Sara Sukumar, Ph.D., Professor of Oncology and Pathology, Johns Hopkins University
Biomarker Discovery: Mining the Cancer Epigenome
Jared Ondrway, Ph.D., Senior Scientist and Program Leader, Discovery, Orion Genomics LLC

CANCER MOLECULAR MARKERS
(Shared session with Pathway Analysis)
Developing Pharmacodiagnostics for Cancer
Jan Trost Jorgensen, M.S. Pharm, Ph.D., Principal Scientist, Clinical Research, Dako
Biomarkers and Development of Targeted Therapies
Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline

Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective
Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor
Driving Down Development Costs by Using Biomarkers
Karol Sikora, M.A., MBBCh, Ph.D., FRCR, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC
Detection of Cancer through Circulating DNA
Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)

Panel Discussion
Steps Needed to Translate DNA Methylation Biomarkers to Clinical Chemistry

Historical Notes in Serum-Based Markers: The State-of-the-Art for Molecular Diagnostics

Diagnosing Prion Diseases: Needs, Challenges, and Hopes
Claudio Soto, Ph.D., Distinguished Professor and Director Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, and Chief Scientific Officer and Founder, Amyprion Inc.
Detection of EGFR in Blood May Predict Iressa and Tarceva Response in Lung Cancer
Stephen Little, Ph.D., Chief Executive Officer, DxS Ltd.
Serum HER-2/neu as a Biomarker for HER-2 Positive Metastatic Breast Cancer (MBC)
Walter P. Carney, Ph.D., Head, Oncogene Science, Bayer HealthCare

Improvements in Ovarian Cancer Screening
Garret M. Hampton, Ph.D., Senior Director, Biochemistry & Biomarker Development, Celgene

Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective
Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor
Driving Down Development Costs by Using Biomarkers
Karol Sikora, M.A., MBBCh, Ph.D., FRCR, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC
Detection of Cancer through Circulating DNA
Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)

CANCER MOLECULAR MARKERS
(Shared session with Pathway Analysis)
Developing Pharmacodiagnostics for Cancer
Jan Trost Jorgensen, M.S. Pharm, Ph.D., Principal Scientist, Clinical Research, Dako
Biomarkers and Development of Targeted Therapies
Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline

Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective
Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor
Driving Down Development Costs by Using Biomarkers
Karol Sikora, M.A., MBBCh, Ph.D., FRCR, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC
Detection of Cancer through Circulating DNA
Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)
Bringing Biology and Business to Support the Science

Supporting the science can only be achieved once scientists have the power to manipulate cells by a thorough understanding of how to “reprogram” stem cell behavior. However, the vision to launch a medical revolution takes commitment and cash. Cambridge Healthtech Institute’s Second Annual Commercial Implications of Stem Cell Research continues the advancement of stem cell research by addressing the current reality and currency required to fulfill their power, potential, promise, and profitability.

Scientific Advisory Committee

Joe Bielitzki, DVM, University of Central Florida
Lee Buckler, LLB, Progenitor Cell Therapy
Robert Deans, Atherosys, Inc.
Robert Harman, DVM, Vet-Stem, Inc.
Rosenarie Hurziker, Ph.D., NIH NIDCR
Mark Levenstein, Ph.D., WiCell Research Institute
Deepak Srivastava, M.D., University of California-San Francisco
Evans Snyder, M.D., Ph.D., The Burnham Institute

PLenary Keynotes

Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints
Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.

Partnersing and Alliance Trends
Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline

Kick-Off Keynote

Selling the Stem Cell Dream
Irving Weissman, M.D., Ph.D., Director, Institute of Stem Cell Biology and Regenerative Medicine and Professor of Pathology and Developmental Biology, Stanford University (invited)

Interactive Panel Discussions

Topics to be discussed:
- Basic Biology
- Scale-up
- Regulation
- Funding
- Patient Advocacy Groups
- Public Perception
- Legal Issues

Save the Date!

Thursday, March 1, 5:30 pm - 7:00 pm

“Wines of California & Dinner Reception”

Join us for a wine tasting dinner reception hosted by CHI. We will offer you the opportunity to network while experiencing California food and wine. The visiting wine makers will be pouring featured wines paired at tasting stations. Learn and discern with experts on hand.

Renaissance Parc 55 Hotel located in Union Square, a few blocks from the Moscone. All are invited to enjoy the reception after Thursday’s sessions.

CHI’s Intro-Net: Networking at Its Best! Maximize Your Experience Onsite at the Molecular Medicine Tri-Conference!

The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is only available to registered session attendees of this event.

For more information, visit: www.Tri-Conference.com/intronet.asp

“The Intro-Net was an excellent networking tool for me, and I made several direct meeting connections that have turned into real potential strategic relationships.”
Eric B. D., Chairman/CEO, Genetic Assays, Inc.

www.Tri-Conference.com
Globalization of clinical trials is a growing trend driven by the need to reduce costs, gain access to large patient populations, and a growing consumer market. Making clinical trials more efficient is going to be key for success, and the leaders in this area need to be aware of how this rapidly changing environment can affect their business. This conference will explore strategies for implementing parallel trial design for US and overseas, that involves integrating data from disparate sites. The barriers to managing clinical trial sites overseas for this highly regulated and controlled area will be carefully weighed.

STRATEGIES FOR IMPROVING DRUG SAFETY

- Manage risk proactively to lower candidate attrition
- Decrease failure with pharmacodynamic biomarkers
- Feed information from clinical trials into discovery phase
- Quantitate benefit-risk management
- Review case study in drug-redirecting
- Gain insights from imaging biomarkers
- Select compounds in man
- Choose the right animal model
- Predict human sensitivity
- Develop biomarker assays

SESSIONS INCLUDE:

- Patient Registration and Recruitment
- Regulatory Concerns
- IP Protection
- Protecting Patient Safety
- Ensuring Ethical Compliance
- Managing Global Sites
- Access to Trained Foreign Clinical Investigators
- Approved Facilities, Monitoring Practices
- Handling Data from Disparate Sources
- Drug Registration

“Trends in drug safety is an excellent forum for scientists and clinicians from academia and industry to learn about the needs, advances and opportunities occurring on the other side of the fence.”

Eric A., Molecular Imaging Scientist, GE Healthcare (2006 Alumni)

SESSIONS INCLUDE:

- Cancer Biomarker Development
- Selecting First Dose in Humans
- How Many New Biomarkers do we Need? A Cost-Benefit Analysis of New Biomarkers
- Correlating Imaging With Clinical Experience
- Exploratory IND’s and Microdosing

“Trends in drug safety is an excellent forum for scientists and clinicians from academia and industry to learn about the needs, advances and opportunities occurring on the other side of the fence.”

Eric A., Molecular Imaging Scientist, GE Healthcare (2006 Alumni)
Companies exhibiting will experience a highly qualified audience. Nearly 60% of attendees in 2006 held Director level titles and higher. 47% are from biotech companies, 26% from pharma! 77% of the audience represented the USA, 13% from Europe and 6% from Asia.

Please visit the web site for an updated floor plan and the current 2007 exhibitors and a full listing of exhibit benefits, or call David Karp at 781-972-5483, or Carol Dinerstein at 781-972-5471 for details.

CHI Supports Your Participation!
CHI’s Cooperative Marketing Program
CHI is pleased to help market to your prospect list at a shared cost. We will offer your prospects a discounted rate to attend the conference on your behalf via mailing or email. CHI’s Marketing Manager will customize a specific message to your target audience.

For sponsorship and exhibit opportunities please contact:
Carol Dinerstein, 781-972-5471, dinerstein@healthtech.com
David Karp, 781-972-5483, dkarp@healthtech.com

PRODUCT LAUNCH?
CHI will help market your product launch!
As an exhibitor announcing a new product, your launch news will be included in:
• One Joint ad in a key industry publication
• One Product Update email campaign to over 100,000 prospects and pre-registered delegates
• Product description in a press release announcing product launches at the event
• Corporate listing within an ad in the Program & Event Guide (distributed on-site)

Reserve space by October 30th to receive a discounted rate!
Venue, Hotel and Travel Information

Conference & Exhibit Venue:
The Moscone North Convention Center
747 Howard Street
San Francisco, CA 94103

To make reservations online go to www.Tri-Conference.com/hotel.asp or call 1-800-697-3103 or 415-392-8000 and ask for the Molecular Medicine Tri-Conference group rate.

Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space and rate availability basis. Rooms are limited, so please book early.

A warmly appointed luxury hotel, situated in the heart of San Francisco, the hotel is 2 blocks from the renowned Union Square shopping area and theatre district; within walking distance of the San Francisco Museum of Modern Art and the Yerba Buena Gardens; near the Moscone Convention Center and financial district. You’re just minutes from the East Bay, with convenient access to BART (Bay Area Rapid Transit), and the cable car is only a half-block away.

To make reservations online go to www.Tri-Conference.com/hotel.asp or call 1-800-697-3103 or 415-392-8000 and ask for the Molecular Medicine Tri-Conference group rate.

Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space and rate availability basis. Rooms are limited, so please book early.

A warmly appointed luxury hotel, situated in the heart of San Francisco, the hotel is 2 blocks from the renowned Union Square shopping area and theatre district; within walking distance of the San Francisco Museum of Modern Art and the Yerba Buena Gardens; near the Moscone Convention Center and financial district. You’re just minutes from the East Bay, with convenient access to BART (Bay Area Rapid Transit), and the cable car is only a half-block away.

Venue, Hotel and Travel Information

Travel Information

“Only in San Francisco”
Take a family vacation to discover San Francisco. Enjoy all the “City by the Bay” has to offer. Take a cruise over to Alcatraz, walk along Fisherman’s Wharf, have dim sum in Chinatown, stroll through historic North Beach. Find out more about these and everything else San Francisco has to offer at www.onlyinsanfrancisco.com

Flight Discount:
Discount fares are available on United, United Express, United code share flights (UA*) operated by US Airways, and US Airways Express. You can receive up to a 15% discount off if you or your travel agent calls United’s toll-free number 1-800-521-4041. Reference Meeting ID Number 579YS.

Car Rental Discount:
Special discount rentals have been established with AVIS for this conference. You can reserve online at www.tri-conference.com/hotel.asp or call AVIS directly at 800-331-1600. You must reference your Avis Worldwide Discount (AWD) Number J868190.

Sponsoring Publications:

ALUMNI DISCOUNT
Receive 25% Off Your Registration!
Cambridge Healthtech Institute (CHI) appreciates your past participation at the Molecular Medicine Tri-Conference. Through loyalty like yours, CHI has been able to build this event into a must attend for senior level decision-makers. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 25% off the registration rate. Just check off the box marked Alumni Discount on the registration form to receive the discount!

Please note: Our records must indicate you were an attendee of the Tri-Conference event in the past in order to qualify.

www.Tri-Conference.com
YES! Register me for CHI’s Molecular Medicine Tri-Conference

Moscone North Convention Center • San Francisco, CA

To Register
Web: www.Tri-Conference.com • Phone: 781-972-5400 toll-free in the U.S. 888-999-6288 • Fax: 781-972-5425 • Mail: 250 First Avenue, Suite 300 Needham, MA 02494 USA

REGISTER 3 — 4TH IS FREE

Individuals must register and submit completed registration forms together for discount to apply. Please reproduce this registration form as needed.

1. REGISTRATION INFORMATION

- Mr. Ms. Mrs. Dr. Prof.
- Name: [Name]
- Job Title: [Job Title]
- Company: [Company]
- Address: [Address]
- City/State/Postal Code: [City/State/Postal Code]
- Country: [Country]
- Telephone: [Telephone]
- Fax: [Fax]
- Email: [Email]
- Would you like to receive CHI event updates via fax? [Yes] [No]
- Cardholder’s Address: [Address]
- Cardholder Signature: [Signature]
- Card#: [Card Number]
- Exp Date: [Expiration Date]

2. PRICING INFORMATION

<table>
<thead>
<tr>
<th>Track Pricing (February 28 - March 2)</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-Affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Registration until October 27, 2006</td>
<td>$1495</td>
<td>$845</td>
</tr>
<tr>
<td>Advance Registration until January 26, 2007</td>
<td>$1645</td>
<td>$995</td>
</tr>
<tr>
<td>Registrations after January 26, 2007 and onsite</td>
<td>$1845</td>
<td>$1045</td>
</tr>
</tbody>
</table>

3. PAYMENT INFORMATION

- Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.
- Invoice me, but reserve my space with credit card information listed below. Invoices unpaid two weeks prior to conference will be billed to credit card.
- Invoices must be paid in full and checks received by the deadline date to retain registration discount. If you plan to register onsite, please check with CHI beforehand for space availability.
- Please charge: [AMEX (15 digits)] [Visa (13-16 digits)] [MasterCard (16 digits)] [Diners Club (14 digits)]

4. FAX OR MAIL YOUR REGISTRATION TO:

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494
Phone: 781-972-5400 or toll-free in the U.S. 888-999-6288 • Fax: 781-972-5425 • www.Tri-Conference.com

**Present a poster and save $50:** Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference CD, your abstract must be submitted, accepted and registration paid in full by January 23, 2007. Register online to use the Poster Abstract Submission form or, if you register by phone, fax, or mail, you will receive Poster Abstract Submission guidelines via email.

**Additional Registration Details**

Each registration includes all conference sessions, posters and exhibits, food functions, and a copy of the conference CD.

**Group Discounts**

Special rates are available for multiple attendees from the same organization. Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.

**Handicapped Equal Access**

In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

**Substitution/Cancellation Policy**

In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization
- Transfer your registration to another Cambridge Healthtech Institute program
- Request a refund minus a $100 processing fee per conference

**Note:** Cancellations will only be accepted up to two weeks prior to the conference.

Program and speakers are subject to change.

Video and/or audio recording of any kind is prohibited onsite at all CHI events.